Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors
Journal of Medicinal Chemistry2011Vol. 54(9), pp. 3393–3417
Citations Over TimeTop 10% of 2011 papers
Ted W. Johnson, Steven P. Tanis, Scott L. Butler, Deepak Dalvie, Dorothy M. DeLisle, Klaus Dress, Erik J. Flahive, Qiyue Hu, Jon Kuehler, Atsuo Kuki, Wen Liu, Guy A. McClellan, Qinghai Peng, Michael Plewe, Paul Richardson, Graham L. Smith, Jim Solowiej, Khanh Tran, Hai Wang, Xiaoming Yu, Junhu Zhang, Huichun Zhu
Abstract
HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.
Related Papers
- Characterization and structural analysis of HIV-1 integrase conservation.(2009)
- → Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy(2010)73 cited
- → Integrase inhibitors in the treatment of HIV-1 infection(2010)56 cited
- → Synthesis and HIV-1 Integrase Inhibition Activity of some N-Arylindoles(2008)46 cited
- Synthesis and HIV integrase inhibitory activity of caffeic acid derivatives(2005)